CanSino Biologics (HKG:6185, SHA:688185) said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine ("CS-2036") was officially initiated in Indonesia recently, with the first trial patient case of the Phase I clinical trial being formally enrolled, according to a Friday filing with the Hong Kong bourse.
The CS-2036 is a polio treatment, a non-infectious polio vaccine developed using advanced protein design and virus-like particle (VLP) technology.
The pharmaceutical stocks were down by over 1% on the Hong Kong bourse and over 2% on the Shanghai Stock Exchange in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。